John Campbell

Company: Swarm Oncology

Job title: Chief Scientific Officer

Seminars:

Highly Optimised Autologous T Cell Therapy Following Cancer Vaccination 12:00 pm

Reviewing detailed characterisation of the immune response in cancer patients to neo Ag and TAA vaccination Pioneering the use of immune screening to successfully harvest vaccine-Ag-specific T cells as the basis for T cell therapy Creating highly optimised GMP in vitro expansion of vaccine-Ag specific T-cells for therapy  Read more

day: Day Two

Eliciting the Desired Immune Response for Long Term Clinical Efficacy in Both Personalised & Off-The-Shelf Neoantigen Cancer Vaccines & Cell Therapies 11:31 am

When monitoring the effect of neoantigen therapies, it is important to understand whether observed immune responses will lead to tumour regression. Additionally, determining how targeted neoantigens are actually processed and presented on tumours is vital to ensure the most appropriate neoantigen targets are selected. Furthermore, selecting the right patients, indications, and conditioning regimen to maximise…Read more

day: Pre-Conference Day